(Q52076702)

English

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.

scientific article published in May 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

1 reference

based on heuristic

inferred from title

author name string

Pacini P

1

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Rinaldini M

2

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Algeri R

3

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Guarneri A

4

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Tucci E

5

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Barsanti G

6

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Neri B

7

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Bastiani P

8

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Marzano S

9

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Fallai C

10

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

36

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

8

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

966-975

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Lonidamine: a non-mutagenic antitumor agent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of lonidamine in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of advanced breast cancer with two doxorubicin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy with epirubicin and mitomycin C as first-line treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of epirubicin and lonidamine for treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900068-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(00)00068-X

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 April 2018

http://europepmc.org/abstract/MED/10885599

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52076702&oldid=1584670964"